The effect of omega-3 fatty acid supplementation on oxidative stress in continuous ambulatory peritoneal dialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201212142417N10

Enrollment

Registered

2012-12-27

Start date

2012-04-28

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease. End Stage Renal Disease

Interventions

Treatment - Drugs

Placebo

Cap Omega-3 1000mg 3capsule per day for 6 weeks manufactured by Zahravi company

Intervention 1: Cap Omega-3 1000mg 3capsule per day for 6 weeks manufactured by Zahravi company. Intervention 2: Cap placebofor 6 weeks manufactured by Zahravi company.

Cap placebofor 6 weeks manufactured by Zahravi company

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1)Clinically stable patients without serious disease. 2)continuous ambulatory peritoneal dialysis (CAPD) for at least 3 months. 3)hypertension stage 1(according to JNC VII) or under treatment. Exclusion criteria: 1)history of steatorrhea. 2) malignancy. 3) thrombocytopenia (PLT<100000/mm3). 4) abnormal coagulation profile. 5)need for anticoagulation therapy. 6)psychosomatic disorders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Reduced gluthation. Timepoint: Begining of the study, after 6 weeks. Method of measurement: ELISA kit, U/mL.;Srum superoxide dismutase. Timepoint: Begining of the study, after 6 weeks. Method of measurement: ELISA kit, U/mL.	—

Secondary

Measure	Time frame
Serum Iron. Timepoint: Begining of the study, after 6 weeks. Method of measurement: ELISA kit, mg/dL.;Serum ferritin. Timepoint: Begining of the study, after 6 weeks. Method of measurement: ELISA kit, mg/dL.;Low density lipoprotein(LDL). Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;High density lipoprotein (HDL). Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;Triglyceride. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;Cholesterol. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.	—

Measure

Time frame

Serum Iron. Timepoint: Begining of the study, after 6 weeks. Method of measurement: ELISA kit, mg/dL.;Serum ferritin. Timepoint: Begining of the study, after 6 weeks. Method of measurement: ELISA kit, mg/dL.;Low density lipoprotein(LDL). Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;High density lipoprotein (HDL). Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;Triglyceride. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;Cholesterol. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Firouzeh Moeinzadeh

Isfahan University of Medical Sciences

moinzade@resident.mui.ac.ir+98 31 1668 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026